However, until recently, there has been a lack of data evaluating the relative efficacy of combination regimens in previously treated patients with NSCLC and EGFR mutations, resulting in an unmet clinical need for this specific subpopulation [7]. Here, EGFR is linked to non-small cell lung carcinoma.